This article reviews the most recent advances in androgen receptor-directed therapies for castration-resistant prostate cancer, and new agents under development.
Carlos Dzik, MD
Advertisement
Articles by Carlos Dzik, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Accepts NDA for Mezigdomide Combo in R/R Multiple Myeloma
2
Dostarlimab Yields Sustained Complete Responses in dMMR/MSI-H Rectal Cancer
3
ADCs in the Frontline: Evolving Approaches in Metastatic TNBC
4
Risvutatug Rezetecan Improves Overall Survival in Relapsed SCLC Trial
5